These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 16272631

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
    Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T.
    J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells.
    Mizobuchi M, Ogata H, Hatamura I, Saji F, Koiwa F, Kinugasa E, Koshikawa S, Akizawa T.
    Biochem Biophys Res Commun; 2007 Oct 12; 362(1):11-16. PubMed ID: 17706605
    [Abstract] [Full Text] [Related]

  • 10. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.
    Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N.
    J Clin Invest; 1997 Dec 15; 100(12):2977-83. PubMed ID: 9399943
    [Abstract] [Full Text] [Related]

  • 11. Calcimimetics and hyperparathyroidism.
    Krebs LJ.
    Curr Opin Investig Drugs; 2004 Oct 15; 5(10):1080-5. PubMed ID: 15535429
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P, Legoupil N, de Vernejoul MC.
    Presse Med; 2005 Sep 10; 34(15):1095-100. PubMed ID: 16334889
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D.
    Kidney Int; 2005 Feb 10; 67(2):467-76. PubMed ID: 15673294
    [Abstract] [Full Text] [Related]

  • 18. Highly concentrated calcitriol and its analogues induce apoptosis of parathyroid cells and regression of the hyperplastic gland--study in rats.
    Shiizaki K, Hatamura I, Negi S, Sakaguchi T, Saji F, Imazeki I, Kusano E, Shigematsu T, Akizawa T.
    Nephrol Dial Transplant; 2008 May 10; 23(5):1529-36. PubMed ID: 18156462
    [Abstract] [Full Text] [Related]

  • 19. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol.
    Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M.
    J Am Soc Nephrol; 2006 Mar 10; 17(3):795-804. PubMed ID: 16467452
    [Abstract] [Full Text] [Related]

  • 20. Prevention of uremic bone disease using calcimimetic compounds.
    Olgaard K, Lewin E.
    Annu Rev Med; 2001 Mar 10; 52():203-20. PubMed ID: 11160775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.